May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • G. Zinzanella
    Inst Ophthalmology, Catholic University, Rome, Italy
  • A. M. Minnella
    Inst Ophthalmology, Catholic University, Rome, Italy
  • A. Scupola
    Inst Ophthalmology, Catholic University, Rome, Italy
  • M. C. Savastano
    Inst Ophthalmology, Catholic University, Rome, Italy
  • L. Ziccardi
    Inst Ophthalmology, Catholic University, Rome, Italy
  • S. Petroni
    Inst Ophthalmology, Catholic University, Rome, Italy
  • L. Montrone
    Inst Ophthalmology, Catholic University, Rome, Italy
  • D. Marangoni
    Inst Ophthalmology, Catholic University, Rome, Italy
  • B. Falsini
    Inst Ophthalmology, Catholic University, Rome, Italy
  • E. Balestrazzi
    Inst Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships G. Zinzanella, None; A.M. Minnella, None; A. Scupola, None; M.C. Savastano, None; L. Ziccardi, None; S. Petroni, None; L. Montrone, None; D. Marangoni, None; B. Falsini, None; E. Balestrazzi, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1416. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Zinzanella, A. M. Minnella, A. Scupola, M. C. Savastano, L. Ziccardi, S. Petroni, L. Montrone, D. Marangoni, B. Falsini, E. Balestrazzi; Intravitreal Bevacizumab in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1416. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic retinopathy (PDR) patients.

Methods:: This interventional case series study included seven eyes of 7 patients with bilateral PDR: 6 eyes with PDR already treated with panretinal laser photocoagulation (PRP) and active new vessels (NV) and 1 eye with recurrent vitreous hemorrhages. All eyes were treated with a single intravitreal of 1.25 mg (0,05 ml) of bevacizumab and evaluated by optical coherence tomography (OCT) and fluorescein angiography (at baseline, one month and three months). All patients received or completed PRP after the injection.

Results:: All eyes (n=7) had a regression of all types of NV with an average improvement of visual acuity of 0.10 mean LogMAR units (±0.03, SE); the eye with recurrent vitreous hemorrhages had clearing of bleeding and improvement of 0.96 mean LogMAR units. The eyes with associated macular edema (n=4) had a mean reduction of macular thickness of 117 microns (±39.48, SE). These early effects allowed us to perform or complete safely PRP.

Conclusions:: Intravitreal bevacizumab did not reveal any side effects and resulted in regression of neovascularizations and resolution of vitreous hemorrhages. Association of intravitreal bevacizumab with PRP could be more effective than PRP alone avoiding laser-related complications and vitreo-retinal surgical procedures.

Keywords: diabetic retinopathy • drug toxicity/drug effects • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×